SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Cancer cells
Cancer
Reframing Multiple Myeloma: From Fatal to Chronic and Even Curable
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs.
January 21, 2025
 · 
8 min read
 · 
Kate Goodwin
Drug Development
Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.
January 14, 2025
 · 
1 min read
 · 
Kate Goodwin
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
 · 
5 min read
 · 
Kate Goodwin
Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering
Cardiovascular disease
Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb
Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.
January 10, 2025
 · 
1 min read
 · 
Kate Goodwin
GLP-1
Evidence Mounts for Benefit of GLP-1s Against Heart Disease
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular benefits in the world’s fastest-growing drug class.
January 6, 2025
 · 
6 min read
 · 
Kate Goodwin
Traffic light in green color, with the dusk sky in the background.
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
 · 
2 min read
 · 
Kate Goodwin
Eli Lilly's biotechnology center in California
GLP-1
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
December 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
External view of Bristol Myers Squibb's office California
Alzheimer’s disease
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.
December 19, 2024
 · 
1 min read
 · 
Kate Goodwin
Novo Nordisk advertising flags and logo on facade
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.
December 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Business
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical.
December 17, 2024
 · 
3 min read
 · 
Kate Goodwin
Craftsmen are using silicone adhesives for general and industrial applications.
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
 · 
6 min read
 · 
Kate Goodwin
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of death by 20%.
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Funding
Nuvig Ropes in $161M Series B From Big Pharma Players for Autoimmune Indications
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, BMS and others for its Fc fragment immunomodulator aimed at improving autoimmune dysregulation.
December 5, 2024
 · 
1 min read
 · 
Kate Goodwin
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More